BeiGene: MCLA-129 is currently exploring indications in the field of lung cancer.

Jin10 data reported on August 19, Beida Pharmaceutical stated on the interactive platform that MCLA-129 is a bispecific antibody targeting both EGFR and c-Met, currently exploring indications in the field of lung cancer. A recent Phase II study related to driver gene positivity and MET amplification has completed the enrollment of its first patient. The company will disclose any significant research progress in a timely manner.

View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • 6
  • Repost
  • Share
Comment
0/400
Bbd®vip
· 08-19 05:01
Just go for it💪
View OriginalReply0
Bbd®vip
· 08-19 05:00
Just go for it💪
View OriginalReply0
Bbd®vip
· 08-19 05:00
Just go for it💪
View OriginalReply0
Bbd®vip
· 08-19 05:00
Just go for it💪
View OriginalReply0
Bbd®vip
· 08-19 05:00
Just go for it💪
View OriginalReply0
Bbd®vip
· 08-19 05:00
Just go for it💪
View OriginalReply0
Trade Crypto Anywhere Anytime
qrCode
Scan to download Gate App
Community
English
  • 简体中文
  • English
  • Tiếng Việt
  • 繁體中文
  • Español
  • Русский
  • Français (Afrique)
  • Português (Portugal)
  • Bahasa Indonesia
  • 日本語
  • بالعربية
  • Українська
  • Português (Brasil)